Eli Lilly and CompanyLLYNYSE
Loading
EPS Growth Recovery in ProgressRecovering
Percentile Rank64
3Y CAGR-10.5%
5Y CAGR-24.0%
Year-over-Year Change
Year-over-year earnings per share growth rate
3Y CAGR
-10.5%/yr
Quarterly compound
5Y CAGR
-24.0%/yr
Recent acceleration
Percentile
P64
Within normal range
vs 5Y Ago
0.3x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 19.13% |
| Q3 2025 | -1.27% |
| Q2 2025 | 105.21% |
| Q1 2025 | -37.47% |
| Q4 2024 | 354.63% |
| Q3 2024 | -67.17% |
| Q2 2024 | 32.13% |
| Q1 2024 | 2.47% |
| Q4 2023 | 4116.53% |
| Q3 2023 | -103.25% |
| Q2 2023 | 30.99% |
| Q1 2023 | -30.39% |
| Q4 2022 | 26.71% |
| Q3 2022 | 51.89% |
| Q2 2022 | -47.00% |
| Q1 2022 | 10.50% |
| Q4 2021 | 56.03% |
| Q3 2021 | -24.18% |
| Q2 2021 | 8.51% |
| Q1 2021 | -36.20% |
| Q4 2020 | 75.40% |
| Q3 2020 | -14.86% |
| Q2 2020 | -2.63% |
| Q1 2020 | -2.56% |
| Q4 2019 | 19.08% |
| Q3 2019 | -4.38% |
| Q2 2019 | -68.36% |
| Q1 2019 | 293.64% |
| Q4 2018 | -2.65% |
| Q3 2018 | 552.00% |
| Q2 2018 | -121.55% |
| Q1 2018 | 177.33% |
| Q4 2017 | -400.00% |
| Q3 2017 | -45.05% |
| Q2 2017 | 1010.00% |
| Q1 2017 | -114.29% |
| Q4 2016 | 0.00% |
| Q3 2016 | 2.94% |
| Q2 2016 | 70.00% |
| Q1 2016 | -6.98% |